01_About.
Cancer Therapy Innovation.
01_About.
Introduction.
Trogenix stands at the forefront of cancer therapy innovation, uniting cutting-edge technologies in genomics, synthetic biology, sophisticated oncology disease models, advanced gene therapy systems, and immunotherapy expertise.
This unique convergence of technologies enables us to target solid tumours with unprecedented precision, potentially offering curative ‘one-and-done’, personalised, in situ vaccinations for aggressive tumours.
Our bold and innovative approach leverages proprietary Synthetic Super-Enhancers (SSEs) technology, delivered via state-of-the-art Adeno-Associated Virus (AAV) vectors.
Our purpose is to create breakthrough precision genetic medicines that cure patients with devastating diseases.
_Leadership.
Leadership Team.
Founded in 2023 by world-renowned experts, we’re on a mission to transform cancer treatment paradigms, offering hope where traditional therapies fall short.
_Advisers.
Scientific + Clinical Advisers.
Our diverse scientific and clinical advisers includes world-leading experts in gene regulation, gene delivery, immunotherapy, neurosurgery, oncology and regenerative medicine.
_Investors.
Secured Investment.
Trogenix is funded by leading life science and deep tech investors with a proven track record of advancing revolutionary therapeutic platforms to deliver treatments for the future.
_Values.
Trogenix Core Values.
Our company culture is reflected in our four core values.
01_Positivity
We Act with Positivity.
We are bold in our ambition and innovation, acknowledge risks, and embrace challenges with enthusiasm.
02_Commitment
We Commit.
We are accountable for our goals, act with urgency, and do what we say we will do.
03_Transparency
We Are Transparent.
We maintain transparency in every aspect of our business—our goals, planning, data, communication, successes, and challenges.
04_Camaraderie
We Act with Camaraderie.
We are inclusive, empathise with each other, have fun together, trust each other, and always give our best.
Trogenix has developed a robust pipeline of potentially curative therapies for multiple cancer types, beginning with glioblastoma (GBM).
This diverse pipeline leverages the versatility of our SSE technology, allowing us to rapidly adapt our approach to different cancer types. We are also developing applications beyond oncology, such as regenerative medicine.
03_Pipeline